(Q34786882)

4 August 2017

1 reference

title

Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation (English)

1 reference

4 August 2017

0 references

Youn Seon Choi

1

1 reference

4 August 2017

J Andrew Billings

series ordinal

2

1 reference

4 August 2017

publication date

1 July 2002

1 reference

Journal of Pain and Symptom Management

4 August 2017

published in

1 reference

4 August 2017

volume

24

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

71-90

1 reference

Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A long-term survey of morphine in cancer pain patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Pharmacologic treatment of cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The relationship between opioid use and laxative use in terminally ill cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Efficacy of senna versus lactulose in terminal cancer patients treated with opioids.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A volunteer model for the comparison of laxatives in opioid-related constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Oral naloxone reverses opioid-associated constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

[Treament of morphine-induced constipation with oral naloxone]

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Treatment of opioid-induced constipation with oral naloxone: A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A brief history of opiates, opioid peptides, and opioid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Pharmacological mechanisms of opioid analgesics.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

No tolerance to peripheral morphine analgesia in presence of opioid expression in inflamed synovia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Insights into opioid action in the intestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Organization of the peripheral nervous system: autonomic and sensory ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The central and peripheral influences of opioids on gastrointestinal propulsion

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Intrathecal morphine slows gastrointestinal transit in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Central and peripheral inhibition of gastrointestinal transit in rats: narcotics differ substantially by acting at either or both levels

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Morphine inhibits gastrointestinal transit in the rat primarily by impairing propulsive activity of the small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Ketazocines and morphine: Effects on gastrointestinal transit after central and peripheral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effect of intracerebroventricular administration of morphine upon intestinal motility in rat and its antagonism with naloxone

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Systemic and central effects of morphine on gastroduodenal motility

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Neuropeptides of the gut: A newly discovered major control system

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Minireview opiates, opioid peptides and single neurones

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Morphine no longer blocks gastrointestinal transit but retains antinociceptive action in diallylnormorphine-pretreated rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Constipation in the cancer patient: causes and management.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Gastrointestinal Receptors and Drugs in Motility Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Comparison of potency and duration of action of nalmefene and naloxone.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Sacral reflexes: physiology and clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Safety and tolerance of methylnaltrexone in healthy humans: a randomized, placebo-controlled, intravenous, ascending-dose, pharmacokinetic study.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A comparison of the effect on gastric emptying of alfentanil or morphine given during anaesthesia for minor surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioid-induced delay in gastric emptying: a peripheral mechanism in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Morphine in the evaluation of gastrointestinal disease. A cineradiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioids inhibit neuromuscular transmission in circular muscle of human and baboon jejunum

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naloxone infusion after prophylactic epidural morphine: effects on incidence of postoperative side-effects and quality of analgesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Oral naloxone reduces constipation but not antinociception from oral morphine in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Oral naloxone in opioid-associated constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Oral naloxone in opioid-associated constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Antagonism of morphine-induced respiratory depression with nalmefene

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Prolonged antagonism of opioid action with intravenous nalmefene in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Nalmefene: intravenous safety and kinetics of a new opioid antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone abuse potential

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone and hepatotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effects of long-term therapy with naltrexone on body weight in obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Lack of hepatotoxicity with naltrexone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Assessment of nalmefene glucuronide as a selective gut opioid antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The use of quaternary narcotic antagonists in opiate research

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Inhibition of gastric emptying by enkephalin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Oral methylnaltrexone for opioid-induced constipation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Continuous Infusion of Naloxone in the Treatment of Narcotic Overdose

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Nalbuphine is better than naloxone for treatment of side effects after epidural morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A blinded study using nalbuphine for prevention of pruritus induced by epidural fentanyl.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Prevention of epidural morphine-induced respiratory depression with intravenous nalbuphine infusion in post-thoracotomy patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effects of liver disease on the disposition of the opioid antagonist nalmefene

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Prolonged blockade of opioid effect with oral nalmefene

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effectiveness and safety of intravenous nalmefene for emergency department patients with suspected narcotic overdose: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Prevention of apomorphine- or cisplatin-induced emesis in the dog by a combination of methylnaltrexone and morphine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Intraspinal opiates and itching: a new reflex?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Nausea and vomiting in the postoperative patient-controlled analgesia environment.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Pruritus--itching for a cause and relief?

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: maternal outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Itching after epidural and spinal opiates

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Central mu-opioid receptors are down-regulated in a rat model of cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Cholestasis in the male rat is associated with naloxone-reversible antinociception

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naloxone modulates the perception of itch in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

A controlled trial of naloxone infusions for the pruritus of chronic cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioid peptides and primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Open-label trial of oral nalmefene therapy for the pruritus of cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The pruritus of cholestasis and the opioid system

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opioid antagonists in the treatment of pruritus from cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opiates, sleep and itch.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Randomised crossover trial of naltrexone in uraemic pruritus

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Evidence for mu1-opioid receptor involvement in fentanyl-mediated respiratory depression

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

New and experimental therapeutic roles for naloxone and related opioid antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Potentiation of pentazocine analgesia by low-dose naloxone

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The influence of naloxone infusion on the action of intrathecal diamorphine: low-dose naloxone and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opiate agonists and antagonists discriminated by receptor binding in brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone administration modulates the neuroendocrine control of luteinizing hormone secretion in hypothalamic amenorrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Opiate antagonists in erectile dysfunction: a possible new treatment option? Results of a pilot study with naltrexone

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

The Atwood Hall Health Promotion Program, Federal Medical Center, Lexington, KY. Effects on drug-involved federal offenders

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Three methods of opioid detoxification in a primary care setting. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone pharmacotherapy for opioid dependent federal probationers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Naltrexone augmentation of neuroleptics in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Pharmacology and mechanisms of opioid analgesic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

Selective postoperative inhibition of gastrointestinal opioid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2802%2900424-4

7 January 2021

10.1016/S0885-3924(02)00424-4

Identifiers

DOI

1 reference

4 August 2017

1 reference